The NR2АТ-IFA Antibody assay is a serological enzyme-linked immunosorbent assay (ELISA) for the quantitative determination of antibodies to the NR2 subunit of human NM DA glutamate receptor in serum. According to previous studies elevated NR2 Antibody level indicates prior ischemic stroke and increased risk of near-term cerebral ischemic events especially in patients with preexisting conditions (diabetes, hypertension, atherosclerosis, cardiovascular disorders). The test is intended to be used in conjunction with clinical evaluation and neuroimaging findings.

 

DRD Biotech Ltd. is a research and production company, based in Republic Buryatia, Russia.

Company develops and implements in vitro diagnosticdevices - ELISA-kits and rapid tests(lateral flow) based on innovative biotech and IT-technologies. Our team has broad experience of the IVD market.